Seminars in Nephrology
Volume 29, Issue 2 , Pages 97-104 , March 2009

Chronic Kidney Disease/Bone and Mineral Metabolism: The Imperfect Storm

  • Mark E. Williams, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Mark E. Williams, MD, FACP, FASN, Associate Professor of Medicine, Harvard Medical School, Co-Director of Dialysis, Beth Israel Deaconess Medical Center, 1 Joslin Pl, Boston, MA 02215

References 

  1. Almaden Y, Hernandez A, Torregrosa V, Canckejo A, Sabate L, Fernandez Cruz L, et al. High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J Am Soc Nephrol. 1998;9:1845–1852
  2. Levin A, Bakris GL, Molitch M, Sulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71:31–38
  3. Block GA, Klasssen PS, Lazarus JM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–2218
  4. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int. 2008;73:1296–1302
  5. Nickolas TL, Leonard MB, Shane E. Chronic kidney disease and bone fracture: a growing concern. Kidney Int. 2008;74:721–731
  6. Hamdy NA, Kanis JA, Benetn MN. Effect of alfacalcidiol on natural course of renal bone disease in mild to moderate renal failure. BMJ. 1995;310:358–363
  7. Bouillon R, Bischoff-Ferrari H, Willett W. Vitamin D and health: from mice and man. J Bone Miner Res. 2008;23:974–979
  8. Pasch A. Bone mass gain after parathyroidectomy. Kidney Int. 2008;74:697–702
  9. Andress DL. Adynamic bone in patients with chronic kidney disease. Kidney Int. 2008;73:1345–1354
  10. Brandenburg VM, Floege J. Adynamic bone disease—bone and beyond. Nephrol Dial Transplant Plus. 2008;3:135–147
  11. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1–S201
  12. Go AS, Chertow GM, Fan D, McCulloch DE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1302
  13. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008;74:148–157
  14. Block GA, Temple E, Hulbert-Shearon TE. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31:607–614
  15. Kestenbaum B, Sampson JN, Rudser KD. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16:52–58
  16. Voormolen N. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant. 2007;27:2909–2916
  17. Goodman WG, Goldin J, Juison BD. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478–1483
  18. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB, Gaziano M, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007;167:879–885
  19. Schwarz S, Rivedi BK, Kalantar-Zadeh K, Kovesdy CP. Association of disorders of mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol. 2006;1:825–831
  20. Ketteler M, Rix M, Fan S, Pritchard N, Oestergard O, Chasan-Taber S, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol. 2008;3:1125–1150
  21. Salusky IB. A new era in phosphate binder therapy: what are the options?. Kidney Int. 2006;70:S10–S16
  22. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol. 2007;18:1637–1641
  23. Razzaque MS, Lanske B. The emerging role of the fibroblast growth factor -23-Klotho axis in renal regulation of phosphate homeostasis. J Endocrinol. 2007;194:1–10
  24. Emmett M. What does serum fibroblast growth factor 23 do in hemodialysis patients?. Kidney Int. 2008;73:3–8
  25. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444:770
  26. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab. 2005;90:1519–1524
  27. Burnett SM, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, Finkelstein JS. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res. 2006;21:1187
  28. Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis. 2004;44:250–256
  29. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003;64:2272–2279
  30. Isakova T, Gutierrez O, Shah A, Castaldo L, Holmes J, Lee H, et al. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol. 2008;19:615–623
  31. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) study. J Am Soc Nephrol. 2007;18:2600–2607
  32. Guetierez O, Isakova T, Rhee E, Shah A, Holmes J. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16:2205–2215
  33. Collins MT, Lindsay JR, Jain A, Kelly MH, Cutler CM, Weinstein LS, et al. Fibroblast growth factor-23 is regulated by 1alpha, 25-dihrydoxyvitamin D. J Bone Miner Res. 2005;20:1944–1950
  34. Urena-Torres P, Friedlander G, deVernejoul MC. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int. 2008;73:102–109
  35. Parfitt AM. The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int. 1997;52:3–6
  36. Felsenfeld AJ, Rodriguez M, Aguilera-Tejero A. Dynamics of parathyroid hormone secretion in health and secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2007;2:1283–1287
  37. Dusso AS, Pavlopoulos T, Naumovich L, Lu Y, Finch J, Brown AJ, et al. p21 (WAF1) and transforming growth factor-alpha mediate dietary phosphate regulation of parathyroid cell growth. Kidney Int. 2001;59:855–861
  38. Cozzolino M, Lu Y, Finch J, Slatopolsky E, Dusso AS. p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int. 2001;60:2109–2117
  39. Arcidiacono MV, Sato T, Alvarez-Hernandez D, Yang J, Tokumoto M, Gonzalez-Suarez I, et al. EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease. J Am Soc Nephrol. 2008;19:310–320
  40. Dusso AS, Sato T, Arcidiacono MV, Alvarez-Hernandez D, Yang J, Gonzalez-Suarez I, et al. Pathogenic mechanisms for parathyroid hyperplasia. Kidney Int Suppl. 2006;102:S8–S11
  41. Arcidiacono MV, Cozzolino M, Spiegel N, Tokumoto M, Yang J, Lu Y, et al. Activator protein 2(alpha) mediates parathyroid TGF-{alpha} self-induction in secondary hyperparathyroidism. J Am Soc Nephrol. 2008 [accessed 2008 October 15]. Epub PMID 18579641.
  42. Schoppet M, Shroff RC, Hofbauer LC, Shanahan CM. Exploring the biology of vascular calcification in chronic kidney disease: what's circulating?. Kidney Int. 2008;73:384–390
  43. Ix JH, Katz R, Kestenbaum B, Fried LF, Kramer H, Stehman-Breen C. Association of mild to moderate kidney dysfunction and coronary calcification. J Am Soc Nephrol. 2008;19:579–585
  44. El-Abbadi M, Giachelli CM. Mechanisms of vascular calcification. Adv Chronic Kidney Dis. 2007;14:54–66
  45. Luo G, Ducy P, McKee MD. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386:78–81
  46. Ketteler M, Giachelli C. Novel insights into vascular calcification. Kidney Int. 2006;70:S5
  47. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int. 2006;69:33
  48. Mizobuchi M, Finch JL, Martin D, Slatopolsky E. Differential effects of vitamin D receptor activators in vascular calcification in uremic rats. Kidney Int. 2007;72:9–16
  49. Al-Aly Z. Metabolic acidosis and vascular calcification: using blueprints from bone to map a new venue for vascular research. Kidney Int. 2008;73:37–44
  50. Mendoza FJ, Lopez L, Montes de Oca P. Metabolic acidosis inhibits soft tissue calcification in uremic rats. Kidney Int. 2008;3:407–414
  51. Harrington PE, Fotsch C. Calcium sensing receptor activators: calcimimetics. Curr Med Chem. 2007;14:3027–3034
  52. Moe SM. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 2005;67:760–771
  53. deFrancisco AL, Izquierdo M, Cunningham J, Pinera C, Palomar R, Fresnedo GF, et al. Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet. Nephrol Dial Transplant. 2008;23:2895–2901
  54. Valle C, Rodriquez M, Santamaria R, Almaden Y, Rodriguez ME, Canadillas S, et al. Cinacalcet reduces the set point of the PTH-calcium curve. J Am Soc Nephrol. 2008 [accessed 2008 October 17]. Epub PMID 18632847.
  55. Coyne DW. Cinacalcet should not be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Nat Clin Pract. 2008;4:364–367
  56. deFrancisco ALM, Pinera C, Palomar R. Cinacalcet should be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Nat Clin Pract. 2008;4:366–369
  57. Charytan C. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis. 2005;46:58–66
  58. Health Canada online. Sensipar R no longer indicated for chronic kidney disease patients (stages 3 and 4) not receiving dialysis. [accessed 2008 September 9]. Available from: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2007/sensipar_hpc-cps_e.html.
  59. Chonchoi M, Locatelli F, Abboud HE, Charytan C, de Francicso AL, Jolly S, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis. 2009;53:197–207

PII: S0270-9295(09)00003-5

doi: 10.1016/j.semnephrol.2009.01.002

Seminars in Nephrology
Volume 29, Issue 2 , Pages 97-104 , March 2009

Article Tools

* Image Usage & Resolution